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Psoriasis is a type-1 T cell-mediated, chronic inﬂammatory disease. Since interleukin (IL)-12p70 promotes the
development of type-1 T cells, we investigated whether psoriasis is associated with an increased production of this
cyctokine by blood cells. Results revealed that the production of IL-12p70 by cells of psoriasis patients stimulated
by 1 and 10 ng per mL, but not 100 ng per mL of lipopolysaccharide (LPS) was higher (p¼ 0.03) than that by cells of
healthy volunteers. The production of IL-12p40 by patients cells upon stimulation with 0.1 ng per mL LPS, but not
higher concentrations, was higher (p¼ 0.02) than that by cells of healthy volunteers. No association between IL-
12p70 production by blood cells and the severity of psoriasis was observed, nor was there a difference in the
LPS-stimulated production of this cytokine between cells of the early and late onset type of patients. The
frequencies of the various genotypes for the promoter region of the gene encoding IL-12p40 (IL12B) did not differ
between psoriasis patients and controls. No association was observed between the various IL12B promoter
genotypes and the LPS-stimulated production of IL-12p70 or IL-12p40 by blood cells. Together, psoriasis is not
associated with a promoter polymorphism in the IL12B gene nor with the production of IL-12p70 by LPS-stimulated
blood cells.
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Psoriasis vulgaris is a type-1 T cell-mediated chronic skin
disease characterized by epidermal hyperplasia and infiltra-
tion of inflammatory cells into the affected skin (Uyemura
et al, 1993; Nestle et al, 1994; Schlaak et al, 1994; Nickoloff,
1999). Based on the age at onset of the disease, two types
of psoriasis can be discriminated, the early onset (age at
onset o40 y) affecting about 75% of the psoriasis patients
and the late onset (age at onset  40 y) occurring in
approximately 25% of the cases (Stuart et al, 2002). It has
been reported that type-1/pro-inflammatory cytokines are
predominantly expressed in affected skin lesions (Bos and
De Rie, 1999) and circulation (Austin et al, 1999). IL-12p70,
an important pro-inflammatory cytokine mainly produced by
antigen presenting cells, is believed to play a pivotal role in
inducing type-1 cytokine profiles. This cytokine is a
heterodimer consisting of the IL-12p35 subunit, which is
constitutively expressed and the IL-12p40 subunit, whose
expression is inducible. The two genes for these subunits,
IL12A encoding IL12-p35 located on 3p12–q13.2 and IL12B
encoding IL-12p40 located on 5q31—33, are unrelated
(Warrington and Bengtsson, 1994; Trinchieri, 2003).
Polymorphisms in cytokine or cytokine receptor genes
are associated with susceptibility to auto-immune, inflam-
matory, and infectious diseases (Hall et al, 2000). Recently,
Morahan et al (2002) found an association between IL-
12p70 production, IL12B mRNA expression and a promoter
polymorphism in the IL12B gene, and the severity of
asthma. In earlier studies, polymorphisms in IL-10, tumor
necrosis factor (TNF)-a, and IL-1b were found to be
associated with psoriasis (Asadullah et al, 2001; Reich et al,
2002). Tsunemi et al (2002) found an association between
a single-nucleotide polymorphism (SNP) in the 30-untrans-
lated region (30-UTR) of the IL12B and the susceptibility to
psoriasis vulgaris. As psoriasis is known to be a type-1
cytokine-mediated disease and the promoter polymorphism
described by Morahan et al (2002) was functionally linked to
IL-12p70 production, the aim of this study was to determine
whether psoriasis is associated with an increased produc-
tion of IL-12p70/p40 by lipopolysaccharide (LPS)-stimu-
lated blood cells and whether psoriasis is associated with a
polymorphism in the IL12B promoter region.
Results
As psoriasis is believed to be a type-1 mediated disease,
we first analyzed whether production of IL-12p70 and
IL-12p40 differed between psoriasis patients and healthy
controls. For this purpose, we determined the production of
IL-12p70 and IL-12p40 by whole blood cells in response to
increasing doses of LPS. The results revealed that doses of
1 and 10 ng per mL, but not 100 ng per mL, of LPS resulted
in a significantly higher (p¼0.03) production of IL-12p70
(Fig 1A) by blood cells of psoriasis patients, i.e., 9  3 and
17  4 pg per mL for 1 and 10 ng per mL LPS, respectively,Abbreviations: IL, interleukin; LPS, lipopolysaccharide
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as compared to blood cells of healthy volunteers (1  1 and
4  2 pg per mL, respectively). The production of IL-12p40
by blood cells in response to 0.1 ng per mL LPS, but not
higher doses of LPS, was significantly higher (p¼0.02) in
psoriasis patients (1526  451 pg per mL) than in healthy
volunteers (422  166 pg per mL).
In addition, the LPS-induced production of IL-12p70 and
IL-12p40 by blood cells did not differ among the two onset
types of psoriasis. Furthermore, no association between the
severity of psoriasis, as assessed by the PASI-score, and
the LPS-stimulated IL-12p70/p40 production by blood cells
was found.
Stimulated by the report of an association between a
promoter polymorphism in the IL12B gene and severity of
asthma (Morahan et al, 2002), we investigated whether this
promoter polymorphism was associated with the severity
of psoriasis. The results revealed no differences in the
distribution of the various genotypes of the IL12B promoter
for psoriasis patients (Table I) when compared to the
distribution of the various IL12B genotypes in the control
group (Table I) and the earlier reported distributions
(Morahan et al, 2002). Moreover, no association between
this promoter polymorphism and the severity of psoriasis
was observed. In addition, no differences in the frequencies
of the IL12B promoter genotypes in the two types of
psoriasis were observed.
Next, we collectively analyzed the production of IL-
12p70 and IL-12p40 of the psoriasis patients and healthy
volunteers to investigate whether these values were asso-
ciated with the various IL12B genotypes. In agreement with
the above data, no relation between the production of IL-
12p70 (Fig 2A) and IL-12p40 (Fig 2B) and the genotype for
the IL12B promoter was observed.
Discussion
The first conclusion to be drawn from the present results is
that the LPS-stimulated IL-12p70 and IL-12p40 production
by blood cells is not associated with psoriasis. In agree-
ment, a previously published report showed that the serum
levels of IL-12p70 in psoriasis patients and healthy
volunteers do not differ (Economidou et al, 1999). The
above conclusion is based on the following findings. First,
blood cells of psoriasis patients did not produce more IL-
12p70 or IL-12p40 upon stimulation with 100 ng per mL (but
not lower) doses of LPS than cells of healthy volunteers did.
Second, no association was observed between the severity
of disease and the LPS-stimulated IL-12p70 or IL-12p40
production by blood cells. Furthermore, we could not find a
difference between the two types of onset of psoriasis with
respect to the LPS-stimulated production of IL-12p70 and
IL-12p40 by blood cells. But it should be realized that blood
cells of psoriasis patients did produce more IL-12p70/IL-
12p40 than blood cells of healthy volunteers upon stimula-
tion with suboptimal doses of LPS. These data may indicate
that patients cells are ‘‘primed to a type-1 immune
response’’.
Figure 1
Interleukin (IL)-12p70 (A) and IL-12p40 (B) production by lipopolysaccharide (LPS)-stimulated blood cells of psoriasis patients and healthy
volunteers. In short, blood was diluted four times with medium and then LPS (range 0.1–100 ng per mL) was added. After 24 h incubation at 371C,
the cells were centrifuged and the supernatants were analyzed for the presence of IL-12p70 (A) and IL-12p40 (B) by ELISA’s. Results are from 22
psoriasis patients (open boxplots), either receiving no therapy or topical therapy, and from 11 healthy volunteers (hatched boxplots). The top,
bottom, and middle lines correspond to the 75th percentile, 25th percentile, and median, respectively. Bars extend to the top 90th percentile and to
the 10th percentile of each group. Indicates values significantly different (po0.05) from cells of healthy volunteers.
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The second conclusion pertains to the frequencies of the
various genotypes of the IL12B promoter in psoriasis
patients. Our results revealed that the frequencies of the
various IL12B promoter genotypes in psoriasis patients
were not different from that reported for healthy volunteers
(Morahan et al, 2002). In addition, the frequencies of the
various IL12B promoter genotypes did not differ among the
two types of onset of psoriasis. This is in contrast to other
cytokines, such as IL-1b, TNF-a and IL-10, in which
particular genotypes are associated with the two types of
onset of psoriasis (Asadullah et al, 2001; Reich et al, 2002).
No association between the IL12B promoter genotypes and
the severity of psoriasis was found. It should be noted that
Tsunemi et al (2002) reported an association between an
SNP within IL12B 30-UTR and susceptibility to psoriasis.
That 30-UTR was not functionally linked to production of IL-
12p70 or IL-12p40 whereas the IL12B promoter polymorph-
ism (Morahan et al, 2002) was. We were, however, not able
to confirm such an association between the production of
IL-12p70 or IL-12p40 by LPS-stimulated blood cells and the
genotype for the IL12B promoter in psoriasis patients or
healthy volunteers. This might be due to differences in the
genetic background between our subjects and those
described in the paper by Morahan et al (2002).
Finally, it should be realized that this study was
performed with blood cells, whereas the local production
of IL-12p70 by antigen presenting cells in the psoriatic skin
may be enhanced as compared to non-psoriatic, inflamed
skin (Cheng et al, 2001). Nevertheless, our results indicate
that IL-12 production may not be the key factor involved in
the pathogenesis of psoriasis patients. Therefore, research
should be focussed on the roles of T cells and their
cytokines in the pathogenesis of psoriasis; however, the
observation that suboptimal doses of LPS induced a higher
production of IL-12p70 and IL-12p40 by circulating cells
of psoriasis patients as compared to those of healthy
volunteers supports the hypothesis that psoriasis is a type-
1 cytokine-mediated immune disease.
Materials and Methods
Subjects This study was approved by the medical ethical
committee of the Leyenburg hospital (MEC number: 95–719, The
Hague, The Netherlands) and after obtaining written informed
consent, conducted in 38 psoriasis patients (18 men and 20
women). Seventeen patients received no anti-psoriasis therapy at
Figure 2
Interleukin (IL)-12p70 (A) and IL-12p40 (B) production by lipopolysaccharide (LPS)-stimulated blood cells of patients and healthy volunteers
with the different IL12B promoter genotypes. In short, blood was diluted four times with medium and then LPS (range 0.1–100 ng per mL) was
added. After 24 h incubation at 371C, the cells were centrifuged and the supernatants were analyzed for the presence of IL-12p70 (A) and IL-12p40
(B) by ELISA’s. Results are from eight individuals with the 1.1 genotype (open boxplots), 15 individuals with the 1.2 genotype (hatched boxplots) and
eight individuals with the 2.2 genotype (vertically hatched boxplots) for the IL12B promoter gene.
Table I. Genotype frequencies of the interleukin (IL)12B
promoter in psoriasis patients and controls
Psoriasis patients
IL12B
genotypes
Early onset
(n¼ 27)
Late onset
(n¼ 10)
Total
(n¼37)
Controls
(n¼131)
1.1 5 (0.2)a 3 (0.3) 8 (0.2) 37 (0.3)
1.2 15 (0.5) 6 (0.6) 21 (0.6) 66 (0.5)
2.2 7 (0.3) 1 (0.1) 8 (0.2) 28 (0.2)
aThe numbers in parentheses indicate the ratio between number of
patients with a certain genotype and the total number of patients in a
group. Similarly, ratios were calculated for the controls.
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the moment of inclusion in the study, seven were treated topically
and 14 were treated systemically. Ten of the 38 patients (26%)
(three men and seven women) developed psoriasis at late age and
28 (74%) (15 men and 13 women) developed this disease at an
early stage of life. The mean ages at onset for the two types of
psoriasis patients in this study were 49  3 and 16  3 y,
respectively. The mean psoriasis area and severity index (PASI)-
scores were almost identical. They were 11  2 and 10  1 for the
early and late onset of psoriasis, respectively. As controls, 44
healthy volunteers were included in this study and for the IL12B
gene frequency studies the DNA of 131 patients undergoing
cardiac surgery (Bouter et al, 2002) were analyzed. For this study,
approval of the medical ethical committee of the Leiden University
Medical Center (MEC-number:P168/96, Leiden, The Netherlands)
as well as written informed consent by the controls was obtained.
Blood was drawn into endotoxin-free tubes (Chromogenix
Endotube, Mo¨lndal, Sweden) for assessment of IL-12p70 and
IL-12p40 production by circulating leukocytes and the remaining
blood was used for extraction of DNA and subsequent determina-
tion of the IL12B promoter genotype.
Whole-blood stimulation and ELISA A whole-blood stimulation
was performed to determine the cytokine production by blood
cells. Briefly, blood was diluted four times in RPMI-1640 (Gibco
BRL, Paisley, Scotland, UK) and then incubated for 24 h at 371C
with medium only or medium containing LPS of Escherichia coli
O111:B4 (0.1, 1, 10, or 100 ng per mL; Difco Laboratories, Detroit,
Michigan). Subsequently, the supernatants were collected and
stored at 701C until further analysis.
The amounts of IL-12p70 and IL-12p40 were determined in
these supernatants using commercial ELISAs (IL-12p70; Elipair,
Diaclone Research, Besanc¸on, France and IL-12p40; Biosource
Europe SA, Fleurus, Belgium) following manufacturer’s instruc-
tions. Each sample was assayed in duplicate. The detection limits
were 6 and 31 pg per mL, respectively.
DNA extraction and IL12B promoter polymorphism To assess
the genotype for the IL12B promoter, the following protocol derived
from that described by Morahan et al (2002) was followed. In short,
DNA was isolated from blood after lysis of erythrocytes using
the Wizards Genomic DNA Purification kit (Promega, Madison,
Wisconsin) according to manufacturer’s instructions. We amplified
DNA samples with two primers located in the IL12B promoter
region. The sequences of the primers (Isogen Bioscience,
Maarssen, The Netherlands) are: IL12B-1188 forward 50-
TTTGGAGGAAAAGTGGAAGA-30; IL12B-1188 reverse 50-AA-
CATTCCATACATCCTGGC-30.
PCR reactions were performed in a final reaction volume of
50 mL PCR buffer (containing 2.5 mM MgCl2) using 100 ng of DNA,
10 pmol of each primer, 0.5 mM dNTPs and 0.8 U Amplitaq DNA
polymerase (Perkin–Elmer, Branchburg, New Jersey). The PCR
reaction consisted of one denaturation step of 3 min at 951C, and
subsequently the PCR was done for 30 cycles: 20 s at 951C
followed by 20 s at 551C and 30 s at 721C with a final 2 min
extension at 721C. PCR products were detected after separation
on a 2% agarose gel (Promega).
To type/analyze the polymorphism consisting of a 4 base-pair
insert, we used a restriction enzyme which cuts the allele that
contains the insert. For this purpose, 8 mL of the PCR product were
incubated for 16 h at 371C with 0.3 U Bpl I (MBI Fermentas, St.
Leon-Rot, Germany) in the presence of 2.5 mM S-adenosylmethio-
nine in Yþ /Tangot buffer (MBI Fermentas). The product was
subsequently run on a 10% polyacrylamide gel to visualize the two
alleles. The insert allele was designated ‘‘allele 1’’ and the shorter
allele was termed’’ ‘‘allele 2’’; the various genotypes are referred to
as 1.1, 1.2, and 2.2.
Statistical analysis Statistical analyses were performed using
SPSS for Windows version 11.0. A univariate analysis was used
to determine whether variations in circulating levels of IL-12p70
and IL-12p40 could be attributed to being a patient or control and
to having an early or late onset type of psoriasis. Comparison of
the distribution of the genotypes for the IL12B promoter were
performed using the w2-square test. In addition, we also analyzed
whether the production of IL-12p70 and IL-12p40 were related to
the genotype of the IL12B promoter using a univariate analysis.
Results are means  SEM.
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